Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

1. Recombinantly expressed human cytochromes P450 (rhCYPs) have been underused for the prediction of human drug clearance (CL). 2. Differences in intrinsic activity (per unit CYP) between rhCYP and human liver enzymes complicate the issue and these discrepancies have not been investigated systematically. We define intersystem extrapolation factors (ISEFs) that allow the use of rhCYP data for the in vitro–in vivo extrapolation of human drug CL and the variance that is associated with interindividual variation of CYP abundance due to genetic and environmental effects. 3. A large database (n = 451) of metabolic stability data has been compiled and used to derive ISEFs for the most commonly used expression systems and CYP enzymes. 4. Statistical models were constructed for the ISEFs to determine major covariates in order to optimize experimental design to increase prediction accuracy. 5. Suggestions have been made for the conduct of future studies using rhCYP to predict human drug clearance.

[1]  G. Tucker,et al.  Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. , 1996, The Biochemical journal.

[2]  H. Zhou,et al.  5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity. , 2000, The Journal of pharmacology and experimental therapeutics.

[3]  W. L. Nelson,et al.  Regioselectivity and Enantioselectivity of Metoprolol Oxidation by Two Variants of cDNA-Expressed P4502D6 , 1995, Pharmaceutical Research.

[4]  H. Yamazaki,et al.  Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug–drug interactions , 2000, European Journal of Clinical Pharmacology.

[5]  P. Meier,et al.  Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine‐type polymorphism of drug oxidation , 1984, European journal of clinical investigation.

[6]  G. Tucker,et al.  Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  D. Back,et al.  Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. , 1991, British journal of clinical pharmacology.

[8]  J. Miners,et al.  Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. , 1988, Biochemical pharmacology.

[9]  R. Tukey,et al.  Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. , 1992, Pharmacogenetics.

[10]  A. Parkinson,et al.  Development of a non-high pressure liquid chromatography assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[11]  J. Idle,et al.  4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. , 2002, The Journal of pharmacology and experimental therapeutics.

[12]  A. Y. Lu,et al.  Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[13]  J. Blake,et al.  Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. , 1998, Pharmacogenetics.

[14]  E. Skjelbo,et al.  Inhibitors of imipramine metabolism by human liver microsomes. , 1992, British journal of clinical pharmacology.

[15]  R. Kato,et al.  Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation. , 1994, Pharmacogenetics.

[16]  D. Greenblatt,et al.  Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. , 1998, Journal of pharmaceutical sciences.

[17]  M. Murray,et al.  Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. , 1999, Biochemical pharmacology.

[18]  P. Neuvonen,et al.  Effects of metronidazole on midazolam metabolism in vitro and in vivo , 2000, European Journal of Clinical Pharmacology.

[19]  U. Fuhr,et al.  Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. , 2002, Biochemical pharmacology.

[20]  H. Yamazaki,et al.  A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[21]  Shiew-Mei Huang,et al.  Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Toward a Consensus , 2001, Pharmaceutical Research.

[22]  Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. , 1999, Biochemistry.

[23]  P. Dayer,et al.  Dextromethorphan O‐demethylation in liver microsomes as a prototype reaction to monitor cytochrome P‐450 db1 activity , 1989, Clinical pharmacology and therapeutics.

[24]  P. Neuvonen,et al.  Plasma concentrations of active simvastatin acid are increased by gemfibrozil , 2000, Clinical pharmacology and therapeutics.

[25]  M Schwab,et al.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.

[26]  T Lavé,et al.  Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.

[27]  A. Somogyi,et al.  The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. , 1994, British journal of clinical pharmacology.

[28]  R. Hyland,et al.  Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[29]  F. Guengerich,et al.  Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. , 1994, Cancer research.

[30]  P. Bechtel,et al.  Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. , 1989, British journal of clinical pharmacology.

[31]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[32]  K. Brøsen,et al.  The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors , 1998, European Journal of Clinical Pharmacology.

[33]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[34]  D. Back,et al.  Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. , 1998, British journal of clinical pharmacology.

[35]  J S Harmatz,et al.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[36]  Tucker Gt,et al.  The rational selection of drug interaction studies: implications of recent advances in drug metabolism. , 1992 .

[37]  K. Korzekwa,et al.  Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. , 1994, Cancer research.

[38]  A. Boobis,et al.  Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  H. Yamazaki,et al.  Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. , 2001, Pharmacogenetics.

[40]  B. Ring,et al.  Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.

[41]  J. Bloomer,et al.  Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. , 1994, Chemical research in toxicology.

[42]  J B Houston,et al.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.

[43]  D. Greenblatt,et al.  Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In‐vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A , 1998, The Journal of pharmacy and pharmacology.

[44]  A. Birnbaum,et al.  Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors , 2001, Epilepsy Research.

[45]  K Chiba,et al.  Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.

[46]  P. Angus,et al.  Differential inhibition of human CYP1A1 and CYP1A2 by quinidine and quinine , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[47]  T Yamamoto,et al.  Involvement of CYP1A2 in mexiletine metabolism. , 1998, British journal of clinical pharmacology.

[48]  P Jaillon,et al.  Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[49]  M. Brodie,et al.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. , 1982, British journal of clinical pharmacology.

[50]  P. Dayer,et al.  In vitro forecasting of drugs which may interfere with the biotransformation of midazolam , 2004, European Journal of Clinical Pharmacology.

[51]  D. Greenblatt,et al.  Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. , 2000, The Journal of pharmacology and experimental therapeutics.

[52]  G. Kearns,et al.  Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[53]  L. Wienkers,et al.  Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[54]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[55]  C. Funck-Brentano,et al.  Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. , 1998, Pharmacogenetics.

[56]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[57]  S. Ekins,et al.  Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[58]  S. Wrighton,et al.  Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation , 1997, European Journal of Clinical Pharmacology.

[59]  D. Greenblatt,et al.  Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. , 2000, The Journal of pharmacology and experimental therapeutics.

[60]  K. Chiba,et al.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. , 1998, British journal of clinical pharmacology.

[61]  D. Mansuy,et al.  Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. , 1999, Biochemistry.

[62]  K. Chiba,et al.  Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[63]  D. Casciano,et al.  Cytochrome P450-dependent metabolism of acetaminophen in four human transgenic lymphoblastoid cell lines. , 1994, Pharmacogenetics.

[64]  G. Tucker,et al.  Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. , 2003, British journal of clinical pharmacology.

[65]  S. Wrighton,et al.  The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. , 2002, British journal of clinical pharmacology.

[66]  S. Wrighton,et al.  Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[67]  D. Greenblatt,et al.  Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N‐Desmethyladinazolam in Man , 1998, The Journal of pharmacy and pharmacology.

[68]  A. Somogyi,et al.  Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. , 1999, British journal of clinical pharmacology.

[69]  J. Miners,et al.  Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. , 1993, Biochemical pharmacology.

[70]  P. Beaune,et al.  Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes , 1996, European Journal of Clinical Pharmacology.

[71]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[72]  F. Belpaire,et al.  PHARMACOKINETICS AND DISPOSITION , 1999 .

[73]  Y. Sugiyama,et al.  Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4 , 2000, Pharmaceutical Research.

[74]  H. Yamazaki,et al.  Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[75]  T. Kost,et al.  CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. , 1995, Archives of biochemistry and biophysics.

[76]  F. Guengerich,et al.  Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[77]  C. Crespi.  Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .

[78]  D. Jones,et al.  Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. , 1999, The Journal of pharmacology and experimental therapeutics.

[79]  T. Leemann,et al.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.

[80]  R. Tyndale,et al.  Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. , 2002, Biochemical pharmacology.

[81]  F. Berthou,et al.  Validation of the (ω-l)-hydroxylation of lauric acid as an in vitro substrate probe for human liver CYP2E1 , 1995 .

[82]  T. Walle,et al.  Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. , 1994, The Journal of pharmacology and experimental therapeutics.

[83]  D. Greenblatt,et al.  Biotransformation of Chlorzoxazone by Heptatic Microsomes from Humans and Ten Other Mammalian Species , 1997, Biopharmaceutics & drug disposition.

[84]  Metabolism of 7-benzyloxy-4-trifluoromethylcoumarin by human hepatic cytochrome P450 isoforms , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[85]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[86]  M. Manno,et al.  Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. , 1999, Pharmacogenetics.

[87]  G. Miller,et al.  Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. , 2000, Biochemistry.

[88]  S. Imaoka,et al.  Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes. , 2001, Research communications in molecular pathology and pharmacology.

[89]  K. Chiba,et al.  A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. , 1998, The Journal of pharmacology and experimental therapeutics.

[90]  P. Beaune,et al.  Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. , 1991, Chemical research in toxicology.

[91]  G. Tucker.  The rational selection of drug interaction studies: implications of recent advances in drug metabolism. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[92]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[93]  N. Chauret,et al.  Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[94]  J. Miners,et al.  Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. , 1991, British journal of clinical pharmacology.

[95]  Aiming Yu,et al.  Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[96]  G. Gervasini,et al.  Modulation of midazolam 1-hydroxylation activity in vitro by neurotransmitters and precursors , 2000, European Journal of Clinical Pharmacology.

[97]  D. Back,et al.  Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors. , 1987, British journal of clinical pharmacology.

[98]  C. Regårdh,et al.  Stereoselective metabolism of felodipine in liver microsomes from rat, dog, and human. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[99]  A. D. Rodrigues,et al.  Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[100]  Y Wang,et al.  Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[101]  H. Yamazaki,et al.  Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[102]  M. Gibaldi,et al.  Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[103]  M. Wester,et al.  Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. , 1998, Archives of biochemistry and biophysics.

[104]  U. Meyer,et al.  Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. , 1997, Pharmacogenetics.

[105]  C. Masimirembwa,et al.  Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[106]  H. Iwata,et al.  High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. , 1998, Biochemical pharmacology.

[107]  P M Shaw,et al.  Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. , 1997, The Journal of pharmacology and experimental therapeutics.

[108]  D. Shen,et al.  Comparison of CYP2D6 Content and Metoprolol Oxidation Between Microsomes Isolated from Human Livers and Small Intestines , 1999, Pharmaceutical Research.

[109]  H. Yamazaki,et al.  Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[110]  D. Greenblatt,et al.  Evaluation of SupermixTM as an in vitro model of human liver microsomal drug metabolism , 2002, Biopharmaceutics & drug disposition.

[111]  S. Higuchi,et al.  Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. , 2000, Therapeutic drug monitoring.

[112]  P. Bonnabry,et al.  Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam , 2004, European Journal of Clinical Pharmacology.

[113]  U. Bredberg,et al.  Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[114]  R. Tukey,et al.  Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. , 1993, The Journal of pharmacology and experimental therapeutics.

[115]  C. Funck-Brentano,et al.  CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. , 1993, Pharmacogenetics.

[116]  A. D. Rodrigues,et al.  [O-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[117]  D A Smith,et al.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. , 1995, British journal of clinical pharmacology.

[118]  L. Wienkers,et al.  Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[119]  S. Krähenbühl,et al.  Biotransformation of caffeine by cDNA-expressed human cytochromes P-450 , 2004, European Journal of Clinical Pharmacology.

[120]  A. Madan.  In vitro approaches for studying the inhibition of drug metabolism enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs , 2002 .

[121]  C. Sengstag,et al.  Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[122]  Y Oda,et al.  Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies. , 2001, British journal of anaesthesia.

[123]  T. Kamataki,et al.  CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. , 2002, Biochemical and biophysical research communications.

[124]  R J Riley,et al.  Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[125]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.